



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K	A2	(11) International Publication Number: WO 99/23996 (43) International Publication Date: 20 May 1999 (20.05.99)
<p>(21) International Application Number: PCT/IB98/01918</p> <p>(22) International Filing Date: 6 November 1998 (06.11.98)</p> <p>(30) Priority Data: 08/965,202 6 November 1997 (06.11.97) US</p> <p>(71) Applicant (for all designated States except US): PEKING UNIVERSITY [CN/CN]; 5 Yiheyuan Road, Haidian District, Beijing 100871 (CN).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): ZHANG, Mao, Liang [CN/CN]; Room 619-623, Beijing Aero Space Great Wall Building, 30 Haidian Nan LU, Beijing 100080 (CN). PENG, Chi-Xiu [CN/CN]; Room 619-623, Beijing Aero Space Great Wall Building, 30 Haidian Nan LU, Beijing 100080 (CN). ZHOU, Yu-Fang [CN/CN]; Room 619-623, Beijing Aero Space Great Wall Building, 30 Haidian Nan LU, Beijing 100080 (CN).</p> <p>(74) Agents: XIAO, Jin et al.; CCPIT Patent and Trademark Law Office, 8th floor, 2 Fuchengmenwai Street, Beijing 100037 (CN).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>
<p>(54) Title: METHODS AND COMPOSITIONS EMPLOYING RED RICE FERMENTATION PRODUCTS</p> <p>(57) Abstract</p> <p>Methods and compositions are disclosed which comprise red rice fermentation products, that can be used as natural dietary supplements and/or medicaments for the treatment or prevention of hyperlipidemia and associated disorders and symptoms, such as cardiovascular diseases, cerebrovascular diseases, diabetes, hypertension, obesity, asthenic breathing, chronic headache, chest pain and tightness, limb swelling and distention, loss of appetite and excess expectoration. The methods and compositions are effective in lowering both the serum cholesterol and serum triglyceride levels in human, and can be used for maintaining cardiovascular health. The invention also encompasses particular <i>Monascus</i> strains that yield fermentation products with the desired biological activities.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHODS AND COMPOSITIONS EMPLOYING RED RICE FERMENTATION PRODUCTS

Field of the Invention

5 The invention relates to the fields of rice fermentation and treatment of hyperlipidemia. More particularly, the invention relates to red rice fermentation products and methods, and use of the products to treat high cholesterol levels and other disorders.

Background of the Invention

10 The invention relates to compositions comprising red rice fermentation products, that can be used as dietary supplements and/or therapeutic medicaments. For example, the compositions can be used to lower serum cholesterol and triglycerides in mammals. Further, the invention relates to methods of treating
15 cardiovascular disorders and other diseases using the red rice fermentation products. In addition, the invention relates to particular *Monascus* strains that yield fermentation products with the desired biological activities.

Red Rice in Ancient China

20 Red rice is known mostly for its use in food as a preservative and colorant, and its uses in the dye industry. Red rice (known in Chinese as Hung-ch'u or Hongqu) has also been known and used for hundreds of years in China in rice wine making and as a food preservative. In addition, red rice has been known as an ancient Chinese medicine or an ingredient in certain ancient Chinese prescriptions.

25 Red Rice was first used around the time of the Han Dynasty. Tao Gu, who lived in the age of Wudai after the Tang Dynasty, recorded "Red Yeast Rice Cooked with Meat," in *Qing Yi Lu*. The method of making Red Rice was originally recorded in *T'ien Kyng K'ai Wu* and *Pen Ts'ao Kang Mu*. A detailed description of the medical applications of red rice was provided in the ancient Chinese pharmacopoeia, *Pen*
30 *Ts'ao Kang Mu*, which was published during the Ming dynasty (1368-1644). In *Pen Ts'ao Kang Mu*, Red Rice is described as mild, nonpoisonous, and useful for treating

indigestion and diarrhea. Red Rice is also described as useful for improving blood circulation and promoting the health of the spleen and stomach. Furthermore, several "prescriptions" using red rice for treating ailments, such as indigestion, diarrhea, and heart and abdominal pains, are also provided in this ancient work. In accordance with the Traditional Chinese Medicine Standard set forth in *Pharmacopoeia of People's Republic of China* and the Traditional Chinese Medicine standard of Beijing, Nei Mongol, Shadog Provice, Jiangsu Province and Hunan province, etc., Red Rice is specified to be used as a traditional Chinese medicine. Furthermore, in the textbooks of Chinese universities and colleges such as *Food Additives* and *Food Chemistry*, Red Rice is considered as additives for food and beverages, and has been widely used in the food processing industry for the production of such items as fermented bean curd, beer, and meat.

In an abbreviated English translation of Pen Ts'ao Kang Mu published in 1911, red rice is described as useful for fermentation, and having medicinal value in the treatment of postpartum difficulties in women and dyspeptic conditions of children (Stuart, M.D., in "Chinese Materia Medica--Vegetable Kingdom," page 233-234, republished in 1979 by Southern Materials Center, Inc., Taipei, Republic of China). Red rice, as described in Pen Ts'ao Kang Mu, was subsequently recognized to be the fungal species known as *Monascus purpureus* Went (Read, B.E., 1936, Chinese Medicinal Plants from the Pen Ts'ao Kang Mu, 3rd edition, published by Peking National History Bulletin; Klein, G., 1932, Handbuch der Pflanzenanalyse II, p. 1422-1423, Wien, Verlag von Julius Springer).

The manufacture of red rice is taught in another publication from the Ming dynasty, T'ien Kung K'ai Wu by Sung Ying-Hsing, which was published in 1637 A.D. (see pages 291-294 in English translation of this ancient writing, "T'ien Kung K'ai Wu--Chinese technology in the seventeenth century," translated by E-tu Zen Sun and Shiou-Chuan Sun, The Pennsylvania State University Press 1966). Red rice is described therein as useful for preserving the color and taste of fish or meat. The manufacturing process used red wine mash and cooked nonglutinous rice as starting materials. The method of making red rice by allowing the fungus to grow on the surface of cooked rice was also recorded by Voderman (1894, *Analecta ob Cromatologisch Gebied. II. Geneesh. Fylschrift voor Ned. Indie*, 35, No.5).

Modernly, red rice, the fermentation product of *Monascus* species, is still used in traditional Chinese medicine, wine making and food coloring in Asia and Asian communities in North America. The red and yellow pigments of *Monascus purpureus*, such as monascorubin and monascin, have been purified and extensively studied (Fielding et al., 1961, J Chem Soc, 4579-4589). The culture conditions and its effect on pigmentation of *Monascus purpureus* have also been studied (Broder et al., 1980, J Food Sci, 45:567-469). Antibacterial activity, especially against *Bacillus* species, was also detected in *Monascus purpureus* extract (Wong, 1977, Plant Physiol, 60:578-581). The Red Rice of the traditional methods has been shown to be of little value and thus has gradually fallen out of use in medical applications. The traditional Red Rice has little effect of reducing blood lipids, and thus has never been used as a cholesterol lowering agent.

Hyperlipidemia and Dietary/Medical Intervention

Lipids and lipoproteins play an essential role in transporting fat-derived metabolites between organs for absorption, metabolism, and distribution (Felig et al., 1975, N Eng J Med, 293:1078-1084). The susceptibility to dietary-induced elevations in blood lipids including cholesterol is extremely common. The interaction of genetic predisposition and a high fat, high caloric diet coupled with underactivity can lead to heart disease, hypertension, hypertriglyceridemia, and diabetes in a significant proportion of the United States population.

High serum cholesterol is a major risk factor for coronary artery disease. Cholesterol is a major component of atherosclerotic plaque. Other associated lipid abnormalities, including hypertriglyceridemia especially in the presence of lowered HDL cholesterol levels, have been recognized as contributing to the risk of cardiovascular disease. There is a reciprocal relationship between elevated triglyceride levels and lowered HDL levels.

The level of cholesterol in circulation results from the balance between production of apoB-100 particles and its removal from the circulation. Cholesterol is synthesized from acetyl-CoA via a series of more than 20 enzymatic reactions. This biosynthetic pathway is mainly regulated by the activity of HMG-CoA reductase (hydroxymethylglutaryl coenzyme A reductase), which catalyzes the reduction of

HMG-CoA to mevalonate. Since the majority of cholesterol circulating is endogenously synthesized in the liver, and not derived from dietary cholesterol, inhibitors of enzymes that are involved in the biosynthesis of cholesterol have been explored as drugs for the treatment of hypercholesterolemia (Grundy, New Eng J Med (1988) 319:24-33).

One class of compounds inhibits cholesterol biosynthesis by competing with a natural substrate (HMG-CoA) for the key enzyme in the cholesterol biosynthetic pathway, HMG-CoA reductase. The first such hypocholesterolemic compound discovered was compactin, which was isolated from cultures of *Penicillium citrinum* by Akira Endo (Endo et al., J Antibiotics (1975) 29:1346-1348, see also US 3,983,140, 4,049,495, and 4,137,322). The hypocholesterolemic activity of this compound was demonstrated in several animal species (Tsuji et al., Atherosclerosis (1979) 32:307-313). Thereafter, a hypocholesterolemic compound structurally related to compactin was independently discovered by Endo in fermentation products of *Monascus ruber* (the active compound was named monacolin K; Endo, J Antibiotics (1979) 32:852-854; Endo, J Antibiotics (1980) 33:334-336; see also German patents DE 3051175, 3051099 and 3006216; British patents GB 2046737 and 2055100), and by another group from cultures of *Aspergillus terreus*. The active compound was also named mevinolin, lovastatin or Mevacor®; Tobert et al., J Clin Invest (1982) 69:913-919), and has been available in the United States since 1987 as a prescription drug. The efficacy and long term adverse effect of this active compound has been reviewed (Tobert, Am J Cardiol, 62:28J-34J). The isolated active compound, its derivatives and methods of production from *Aspergillus* have been reported; see U.S. patent nos. 4,231,938, 4,342,767, 4,294,926, 4,319,039, 4,294,926, 4,294,846, and 4,420,491.

Although monacolin K or mevinolin has been successfully used to treat hypercholesterolemia, the compound has little or insignificant effect on the serum level of triglycerides. Other lipid regulating agents that have been used to treat hypertriglyceridemia, especially type IV and V hyperlipidemia, include nicotinic acid (e.g., niacin), and fibric acid derivatives (e.g., gemfibrozil and clofibrate). However, the uses of such agents are restricted because of their side effects, for example, high doses of niacin may cause gastric irritability, hyperuricemia, hyperglycemia, pruritus, and gemfibrozil may lead to malignancy, gallbladder diseases, and abdominal pain.

Moreover, the risk of myositis and rhabdomyolysis that can result in renal failure increases when monacolin K is combined with gemfibrozil, clofibrate or niacin. Such combinations are only used with careful supervision in special situations that warrant the risk (The Merck Manual, 1992, 16th edition, pages 1044-1046). High concentrations of serum triglycerides are known to be a risk factor for a variety of disease states and can lead to medical complications. Thus, there is a need for the development of a composition that accomplishes the reduction of the serum levels of both cholesterol as well as triglycerides. Regular exercise, proper nutrition, and weight reduction programs can prevent or reduce the incidence of common chronic diseases such as heart disease associated with elevations of blood lipids (Pi-Sunyer, Am J Clin Nutr (1991) 53:1595S-1603S). The role of diet in maintaining optimal health, and in slowing and reversing the progression of disease, has been the subject of much research and public attention. The development of an effective dietary supplement for use in the treatment of mixed hyperlipidemia, which could be used either with or without dietary changes, would be a significant benefit.

SUMMARY OF THE INVENTION

The invention relates to a product of the fermentation of at least one *Monascus* strain that can be used as a dietary supplement or as a therapeutic medicament to lower both serum cholesterol and triglyceride levels in humans. The invention is based, in part, on the surprising discovery that certain red rice products, i.e., the product of the fermentation of certain strains or mixtures of strains of *Monascus*, are effective at lowering not only the level of serum cholesterol but also the level of serum triglyceride in mammals, particularly humans. Since monacolin K and mevinolin are not known to be significantly effective in lowering serum triglyceride level, the beneficial effect of red rice products is likely to be related to other components in the fermentate.

In various embodiments of the invention, red rice can be used as a natural dietary supplement or a medicament to treat or prevent a variety of diseases, including but not limited to cardiovascular diseases, diabetes, fatty liver conditions, stroke, cerebral thrombosis, hypotension, hypertension and obesity, and to modulate the circulating levels of lipids, such as cholesterol and triglyceride. In addition, the

present invention encompasses methods for treating or preventing these diseases in a human, which comprise administering to the human a therapeutically effective amount of a red rice fermentation product. The present invention also encompasses methods for improving or maintaining cardiovascular health in a human comprising administering to an effective amount of red rice fermentation product. The present invention further encompasses methods for reducing the serum cholesterol and serum triglyceride levels to normal levels in a human comprising administering to the human a therapeutically effective amount of a red rice fermentation product. Red rice can also be used to treat or prevent a variety of ailments or symptoms as related to diseases of the cardiovascular system.

According to the invention, red rice can be manufactured in various dosage forms and formulations. Also disclosed are methods for manufacturing red rice which are based on the traditional fermentation procedures.

The terms "red rice fungi" or "*Monascus*" as used herein refer to the prefermented organism, while the terms "red rice," "red rice product", "red rice extract" and the like refer to a product that results from the fermentation of at least one *Monascus*. Further, these latter terms include traditional and improved red rice products as described below. More specifically, "red rice product" as used herein refers to the product of fermentation, e.g., the fermentate of one or a mixture of *Monascus* fungus. A "lovastatin-producing" *Monascus* strain (such as strain 0272) is one which can be fermented to produce a product having a lovastatin content of at least 0.05%, preferably at least 2%.

The red rice product is the fermentation product of at least one of the following *Monascus* fungi set forth in the table below

Red rice is the fermentation product of one or a mixture of *Monascus* fungi, comprising chiefly *Monascus purpureus* Went, and in lesser proportions other *Monascus* species, e.g., *Monascus ruber* van Tieghem, *Monascus Fuliginosus* Sato, *Monascus Pilosus* Sato and *Monascus albidus* Sato. Red rice can also be the fermentation product of the following strains of *Monascus* fungi:

Strains	Accession No.
<i>Monascus albidus</i> Sato	AS 3.570
	AS 3.4440
	CGMCC No. 0317
<i>Monascus pilosus</i> Sato	AS 3.4444
	AS 3.4633
	AS 3.4646
	AS 3.4647
<i>Monascus pubigerus</i> Sato	AS 3.4445
<i>Monascus ruber</i> van Tieghem	AS 3.549
	CGMCC No. 0315
	CGMCC No. 0316
<i>Monascus paxii</i> Lingelsheim	AS 3.4453
<i>Monascus fuliginosus</i> Sato	AS 3.569
	AS 3.1098
	AS 3.2091
	AS 3.2093
	AS 3.2134
	IFFI 05035
<i>Monascus purpureus</i> Went	CGMCC No. 0272

- 25 *Monascus purpureus* Went ATCC 30141, AS 3.562, AS 3.991, AS 3.4446 [ATCC 16365], AS 3.4642 [NRRL 2897], AS 3.4643 [NRRL 96], AS 3.4644, AS 3.4645, AS 3.4651; *Monascus ruber* van Tieghem AS 3.549, IFFI 05007, IFFI 05008, IFFI 05010, IPPI 05011; and *Monascus anka* IFFI 05038 (reference numbers provided in China Catalogue of Cultures, 1992, China Committee for Culture Collection of Microorganism, China Machine Press, Beijing 1992). The improved red rice of the invention comprises *Monascus purpureus* Went mutant strain M4027, 4028 and M4184.

The term "traditional red rice" as used herein refers to a red rice product which

is the result of fermentation using a mixture of *Monascus* fungi that has been used traditionally to manufacture red rice. "Traditional red rice" will generally contain less than about 0.005% lovastatin by weight. According to the invention, an "improved red rice" is produced by fermentation using one or more natural or mutant strains of *Monascus* species, which yield a fermentate with improved biological or nutritional properties, e.g., higher hypocholesterolemic and hypotriglyceridemic activities than traditional red rice. The improved red rice of the invention comprises *Monascus purpureus* Went mutant strain CGMCC No. 0272. Several other strains can be used to achieve the objectives of the invention. Improved red rice is sometimes referred to as Xuezhikang herein.

Generally, the red rice products of the present invention are red-purple powders that have a slightly bitter but mild and pleasant taste. Similarly, the red rice products have a pleasant odor. The color and/or odor may vary with the fermentation process, the strains used and the processing steps. The red rice products of the invention contain at least 0.05% lovastatin, more preferably at least about 2.0% lovastatin by weight.

As used herein, the term "effective treatment" means the reduction of a particular symptom, or the significant change of a particular laboratory test toward the normal value. Preferably symptoms are relieved by at least 30-70% and a laboratory test is moved at least 10% toward the normal value; more preferably symptoms are reduced by 70% and/or a laboratory test is moved at least 20% toward the normal value; most preferably, a treatment is effective if the symptoms are reduced by 90%, and/or laboratory parameters are returned to the normal value.

The term "hypercholesterolemia" means the presence of elevated levels of cholesterol in the blood.

The term "therapeutically effective amount" or "therapeutic dose" as used herein means the amount of a particular agent sufficient to provide a therapeutic benefit in the treatment or prevention of a disease, or in modulating the level of serum lipids and lipoproteins.

The term "dietary supplement" as used herein means an additional element that is added to the daily food intake of a mammal, usually a human.

Unless otherwise defined, all technical and scientific terms used herein have

the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and material similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent
5 applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages will be apparent from the following detailed
10 description, and from the claims.

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to compositions comprising the product of the fermentation of at least one *Monascus* species. These compositions are useful for
15 reducing the levels of both serum cholesterol and serum triglycerides in mammals, and in particular humans. In addition, the compositions are useful for modulating the levels of both serum cholesterol and triglycerides to maintain healthy levels despite intrinsic (e.g. aging) or extrinsic (e.g. stress) factors that affect serum cholesterol and triglyceride levels. The compositions and methods of the present invention are based,
20 in part, on the discovery that the fermentate of *Monascus* species display hypocholesterolemic properties and also, unexpectedly, the ability to lower serum triglyceride levels. Since monacolin K is known not to be significantly effective in lowering serum triglyceride level, the beneficial effect of red rice products must be related to other components of the fermentate. The ability of red rice products to
25 lower serum triglyceride level provides the art with a unique, natural alternative to the use of prescription hypocholesterolemic compounds.

According to the invention, traditional or improved red rice can be prepared by traditional fermentation procedures or by modification of the traditional procedures. According to the earliest reported method (Sung, 1637, T'ien Kung K'ai
30 Wu; pages 291-294, English translation by Sun et al., Pennsylvania State Press 1966), red rice can be prepared by the fermentation of washed and cooked nonglutinous rice using red wine mash, natural juice of *Polygonum* grass, and alum water. The rice is

fermented in open air for 7 days on bamboo trays under very clean conditions. The rice changes its color from white to black, black to brown, brown to red and then red to yellow, which is then harvested as red rice. According to an alternative traditional method, nonglutinous rice can be fermented in a hole in the ground lined by bamboo mats, which is securely covered. Fermentation is allowed to take place underground for one year or more, up to four years.

With respect to the present invention, the traditional method has been improved by use of modern fermentation techniques and equipment to more precisely control temperature, pH, pressure and other fermentation parameters, which, *inter alia*, reduces the time of fermentation. The key feature of the improved red rice preparation is that it contains active ingredients that can prevent or treat hyperlipidemia and related cardiovascular diseases. The preparations can be made as follows:

15 Preparation of Conventional Culture Fluid

For all of the media preparations rice or another grain is used as a carbon source. The carbon source can be rice (polished long-grain nonglutinous rice, polished round-grain nonglutinous rice, polished glutinous rice, red rice, and black rice), millet, barley, wheat, or corn. Additionally sugar and substances containing sugar can be used. Organic compounds such as glycerine and glyceride can also be used in the media preparations. For each 100 g of polished round-grained nonglutinous rice, 30-80 ml of culture medium are added. The culture media's key feature is that the carbon source is selected from the group consisting of cereals, sugar, and organic compounds, the source of nitrogen is selected from the group consisting of beans (e.g. soya bean powder, pressed soybean cake), or peanut powder (or pressed peanut cake), peptone, rice extract powder, thick beef juice, silkworm chrysalis powder, or inorganic salts (e.g. NH_4NO_3 , etc.), and a source of phosphorous can also be added, such as inorganic salts (e.g. KH_2PO_4 , K_2HPO_4 , etc). Other inorganic salts can also be added, such as MgSO_4 or FeCl_2 . By way of an example, and not by limitation, media preparations of the invention are listed below:

Media 1: Liquid strain

- 2-7% glycerine (or malt or potato juice)
2-6% sugar
0-3% peptone
5 0.5-3% yeast extract powder
0-3% thick beef juice (optional)
2-4 % defoamer (e.g. bean oil or peanut oil)
water

10 Media 2: Solid strain.

- 0-5% Potato juice
0-6% sugar
0-1.5% yeast extract or peptone
30-80 ml of water per 100 g rice

15

Media 3:

- 2-4% potato juice
2-6% sugar
0.5-3% yeast extract powder (or peptone or thick beef juice)
20 water.

Approximately 40-80 ml of the mixture is added to each 100 g of rice, the pH is maintained at 3-8, and it is sterilized in steam at 121 °C.

Generally, the pH is adjusted to 3.0-5.0, and the mixture is steam sterilized (121 °C).

- 25 The mixture is cooled to 40 °C, and the rice is inoculated with the a *Monascus* strain of the invention. For example, the *Monascus purpureus* Went strain CGMCC No. 0272 is added and cultured at 15-35 °C for 9 days. Fermentation of the rice mixture is preferably carried out at a temperature of 15-35 °C, most preferably 20-28 °C, for over 4 days, most preferably 9 days or more, until the formation of Red Rice is noted.
- 30 Any one of a number of methods of fermentation, well known to one of skill in the art, can be used. For example, an Erlenmeyer flask, tray, or ventilated fermentation bed can be used as fermentation facilities. At the end of the fermentation process, the

fermentation broth is drained and discarded, while the solid residue is sterilized by heat (for example, by high pressure steam). For example, the fermentation product is sterilized at a temperature of 69-121°C, and dried. This dried product can be ground. Standard mesh sizes for the production of capsules, tablets, powders and suspensions are well known in the art. By way of example, the improved red rice of the invention can be ground to 80 mesh under vacuum at a temperature of approximately 60-80°C, and the powdered product recovered. This product can be used directly in the various compositions and formulations provided by the present invention. For example, it can be filled into capsules. Alternatively the 80 mesh ground product can further be ground to 200 mesh. The 200 mesh powder can then be formulated into tablets using standard methodologies. Alternatively, liquid or syrup formulations of red rice can be made using conventional procedures.

Optionally, the dried crushed red rice powder can be further processed, e.g., extracted with organic solvents, such as but not limited to, alcohols (e.g. 75-90% ethanol) to remove starch and/or agar. After evaporation to dryness, the extract can be used in the various compositions and formulations as provided by the present invention. The extracted product can further be concentrated under a vacuum and evaporated (60-80°C, 0.06-0.08 MPa) until dry. This provides an exceptionally useful supplement at very low cost.

According to the invention, an "improved red rice" is produced by fermentation using one or more natural or mutant strains of *Monascus* species, which yield a fermentate with improved biological or nutritional properties, e.g., higher hypocholesterolemic and hypotriglyceridemic activities than traditional red rice. The improved red rice of the invention comprises *Monascus purpureus* Went mutant strain M4027, 4028 and M4184. Several other strains can be used to achieve the objectives of the invention (Chinese Microorganism Strain Index, 1992, China Microorganism Collection Committee), as listed in the Table above.

Lovastatin in red rice may be extracted using 10 ml of 75% EtOH at ambient temperature. The extract (2 ml) is treated with 1 ml 0.06 M NaOH in 75% EtOH for 30 min, then with 1 ml 0.06 N H₃PO₄ (in 75% EtOH), and the mixture applied to a C18 HPLC column (150 x 4.60 mm), and developed with 0.02 N H₃PO₄ (in 70% MeOH) to quantify the amount of lovastatin present.

Red rice can be used as a natural dietary supplement or a pharmaceutical medicament to prevent illness (maintain health) or to treat or a variety of diseases, including but not limited to cardiovascular diseases, diabetes, stroke, hypertension and obesity, and to modulate the circulating levels of lipids and lipoproteins, such as cholesterol and triglycerides. Red rice can also be used to treat or prevent a variety of symptoms related to these above-mentioned diseases and associated with poor cardiovascular health due to aging and other intrinsic and extrinsic factors.

As used herein, examples of cardiovascular diseases may include but are not limited to myocardial infarction, coronary heart disease, atherosclerosis, arteriosclerosis. The present invention includes the treatment or prevention of cerebrovascular disease such as stroke, memory loss due to stroke, and cerebral thrombosis.



The present invention also encompasses a composition comprising a therapeutically effective amount of a red rice product, for example 2-4 grams per day, useful in humans for the treatment or prevention of hyperlipidemic disease, cardiovascular disease, cerebrovascular disease, hypertension, hypotension, diabetes, fatty liver conditions, or obesity, or a combination thereof.

The present invention further encompasses a composition comprising a therapeutically effective amount of a red rice product, useful for the modulation of serum lipid and lipoprotein levels in a human in need of therapy to maintain the lipid and lipoprotein levels within a healthy normal range. In one embodiment of the invention, the composition is adapted for use in the treatment or prevention of hypertriglyceridemia. In a preferred embodiment, such a composition is used for reducing serum cholesterol and serum triglyceride levels in humans.

The present invention further encompasses a composition comprising a therapeutically effective amount of improved red rice product, useful for the treatment of any one of the following symptoms: shortness of breath; asthenic breathing; lethargy; dizziness; chronic headache; chest pain and tightness; heartache; loss of appetite; limb swelling; tightness and distention.

Functions of Improved Red Rice

The improved red rice of the invention and preparations of the improved red



Lovastatin - hydroxy acid

Lovastatin - lactone

rice contain statinoid compounds, i.e. hydroxy-acid Lovastatin and lactone Lovastatin.

Without being bound by theory, the above-mentioned *Monascus* strains, when cultured under the appropriate fermentation conditions, have an increased content of the statinoid compounds. The increase in the statinoid compounds reduces serum cholesterol and serum triglycerides, while increasing high-density lipoprotein cholesterol simultaneously.

The red rice of the invention can be employed to treat hyperlipidemia and other related cardio-cerebrovascular diseases, such as atherosclerosis, coronary heart disease, myocardial infarction, diabetes, hypertension, and cerebral embolism, among others.

Method of Treatment

The present invention provides methods for treating a human afflicted by a variety of diseases, disorders, and symptoms. In addition to treatment of a human disease, the methods of the invention can also be used for preventive treatment in a person susceptible to such diseases, disorders or symptoms.

The invention encompasses methods of treatment of hyperlipidemic disease, cardiovascular disease, cerebrovascular disease, hypertension (hereditary and non-hereditary), hypotension, angina, stroke, diabetes, fatty liver conditions, or obesity, or a combination thereof in a human, comprising administering to the human a therapeutically effective amount of a red rice product, or compositions containing said

product.

The invention also encompasses methods of preventing hyperlipidemic disease, cardiovascular disease, cerebrovascular disease, hypertension, hypotension, angina, stroke, diabetes, fatty liver conditions such as fatty liver deposits, obesity or a combination thereof, which comprises administering an effective amount of a red rice product of the present invention. The method of the invention is preferably used to treat or prevent hypertriglyceridemia and associated diseases, such as diabetes, in humans.

As used herein, examples of cardiovascular diseases may include myocardial infarction, coronary heart disease, atherosclerosis, arteriosclerosis, and cerebrovascular diseases or conditions, including stroke, cerebral thrombosis or memory loss due to stroke.

The present invention also provides methods for modulating serum lipid and lipoprotein levels in a human in need of lowering the lipid and lipoprotein levels to a healthy normal range, which comprise administering to the human a therapeutically effective amount of a red rice product, or compositions containing said product. In a preferred embodiment, the method of the invention is used to reduce serum cholesterol and serum triglyceride levels in a human. The methods of the invention are particularly useful for the treatment of geriatric patients and postmenopausal women.

The present invention further provides methods for treating a human afflicted by shortness of breath, asthenic breathing, lethargy, dizziness, chronic headache, loss of appetite, limb swelling, tightness and distention, and abdominal distention, or a combination thereof, which comprises administering to the human a therapeutically effective amount of a red rice product, or compositions containing said product.

The preventive or therapeutic dose of traditional red rice or improved red rice in the treatment or prevention of diseases and in the management of serum lipid and lipoprotein levels will vary with the condition to be treated and the severity of the condition to be treated. The dose, and perhaps the dose frequency, will also vary according to the age, body weight, and response of the individual patient. In general, the total daily dose range of red rice, for the conditions described herein, is from about 0.1 g to about 5 g administered in single or divided doses orally. For examples a preferred oral daily dose range should be from about 0.3 g to about 4 g, while most

preferably an oral daily dose should be about 1.2 to about 2.5 g. For example, two capsules each containing 0.6 g of red rice may be taken orally twice a day to obtain the preferred dose. A course of treatment should be at least 4 weeks. It may be necessary to use dosages outside these ranges in some cases as will be apparent to those skilled in the art. Further, it is noted that the nutritionist, dietitian, clinician or treating physician will know how and when to interrupt, adjust, or terminate therapy in conjunction with individual patient response.

It should be noted that the present invention encompasses new uses of traditional red rice, and novel red rice products and novel methods of using those products.

Dietary Supplement Use

As mentioned above, the present invention encompasses compositions and methods of using traditional and novel or improved red rice products as dietary supplements. As such, the red rice products provide the individual with a means for maintaining normal or healthy levels of serum cholesterol and triglycerides despite intrinsic deterioration, e.g., from aging and extrinsic factors such as stress, lack of exercise and poor nutrition. The dietary supplements also provide means for preventing, or reducing the likelihood of experiencing, the diseases discussed above. Finally, the dietary supplements can be used to prevent weight gain or obesity. Finally, the dietary supplements containing red rice products are particularly useful for the elderly and postmenopausal women. The dietary supplements should be taken daily for at least four weeks and can be used permanently on a daily basis. A daily dose is from about 0.1 g to about 5.0 g; preferably about 1 to about 4 g; and most preferably about 1.2 to about 2.4 grams per day.

Formulation

The pharmaceutical and dietary compositions of the present invention comprise a red rice product, or an extract thereof, as active ingredient, and may also contain a pharmaceutically acceptable carrier or excipient and, optionally, other ingredients.

Other ingredients that can be incorporated into the dietary or pharmaceutical

compositions of the present invention may include, but are not limited to, vitamins, amino acids, metal salts and flavor enhancers. For oral administration, the compositions comprising red rice can be added directly to foods so that a therapeutically effective amount of red rice is ingested during normal meals. Any methods known to those skilled in the art may be used to add or incorporate red rice to natural or processed foods.

Compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, each containing a predetermined amount of a red rice product, as a powder or granules, or as a solution or a suspension in an aqueous liquid, a nonaqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.

The compositions of the present invention may additionally include binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); binders or fillers (e.g., lactose, pentosan, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets or capsules can be coated by methods well known in the art.

Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats), emulsifying agents (e.g., lecithin or acacia), nonaqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils), and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations can also be made to resemble foods, containing buffer salts, flavoring, coloring and sweetening agents as appropriate.

Any dosage form may be employed for providing the patient with an effective

dosage of the red rice product. Dosage forms include tablets, capsules, dispersions, suspensions, solutions, capsules and the like. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers as described above are employed. In addition to
5 the common dosage forms set out above, the compounds of the present invention may also be administered by controlled release means. However, the most preferred oral solid preparations are capsules.

For example, a tablet may be prepared by compression or molding, optionally, with one more accessory ingredients. Compressed tablets may be prepared by
10 compressing in a suitable machine red rice in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Most preferably, the composition is a capsule containing 0.3 g of red rice in powder form.

The invention is further defined by reference to the following examples
15 describing in detail the human clinical trials conducted to study the efficacy and safety of red rice. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced which are within the scope of this invention.

The invention will be further described in the following examples, which do
20 are intended to provide further description of the invention, and are not intended to limit the scope of the claim.

Example 1 - Preparation of Red Rice Cultures

(A) A liquid strain culture fluid was prepared containing 2-4% glucose, 3-5
25 % glycerine, 0-3% thick beef juice, 0.8-1.6% peptone, 0-3% yeast extract powder, 0.1% KH_2PO_4 , and 0.05% $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ and water. Two media were prepared, the first containing 2% glucose, 3% glycerine, 1.5% thick beef juice, 0.8% peptone, 3% yeast extract powder, 0.1% KH_2PO_4 , and 0.05% $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ in water, and the second containing 4% malt juice or potato juice, 8% sugar, 1.5% yeast extract
30 powder, 3% thick beef juice, and water. The pH was adjusted to 3.5 using acetic acid. For each 50 ml of culture fluid, 100 g of polished round-grained nonglutinous rice was added, and the media were sterilized in steam at 121 °C. The mixture was cooled

to below 40°C, and inoculated with *Monascus purpureus* Went (CGMCC No. 0272) in glass tubes or plates and cultured at 30-34°C for 24-36 hours. Fermentation was continued at 25°C for 9 days. Once the fermentation period was completed, the mixture was sterilized at high temperature (100-121°C), dried under a vacuum at 80°C, and ground to 60-100 mesh. The powder was then filled into capsules. Yield approximately 65%.

(B) Alternatively, culture fluid containing 4% malt juice or potato juice, 8% glucose, 3% thick beef juice, 3% peptone and water (pH value adjusted to 3) was used. Following fermentation, the resulting product was extracted using 75-95% ethanol, the red rice was dried and fully mixed with untreated rice. Soya bean powder (10 g) and culture fluid (50 ml) were added to each 100 g mixture, and the composition was sterilized. The mixture was cooled to 30-40°C and then inoculated with 10-20 ml liquid *Monascus* strain (CGMCC No. 0272), fermented at 30-34°C for 3-4 days and at 23-25°C for over 15 days. The mixture was sterilized at 100-121°C and dried under vacuum. This red rice product was ground and tablets were produced.

(C) Another medium was prepared using 4% malt juice, 6% malt sugar, 1% yeast extract powder, 6% peptone and water (pH = 3). Soya-bean powder (15 g) and culture fluid (50 ml) was added to each 100 g of polished round-grained nonglutinous rice. The mixture was sterilized at 121°C and then inoculated with *Monascus ruber* AS 3.549 (20 ml). Fermentation was carried out at 25°C for over 9 days. After sterilization, the mixture was dried at 80°C.

The Red Rice was further processed into concentrates using alcohol (75%) extraction twice. After evaporation under vacuum, the concentrated substance was obtained and the alcohol was recovered. The resulting concentrated substance contained approximately 25 mg lovastatin per gram red rice, and was used as raw material for the production of the capsules or tablets.

(D) Another culture fluid was prepared containing 4% malt juice, approximately 8% sugar, 2% yeast extract powder, 5% thick beef juice and water (pH = 3). Culture fluid (50 ml) was added to each 100 g of rice and the mixture was sterilized in steam at 121°C. After cooling below 40°C, the mixture was inoculated with *Monascus albidus* (CGMCC No. 0317) and then fermented at 25°C for over 12 days. The mixture was sterilized and then dried. This Red Rice preparation was

ground to 200 mesh and granulated with alcohol for pill preparation.

(E) Culture fluid was also prepared using 3% potato juice, approximately 6% sugar, 1.5% yeast extract powder, 4% peptone and water (pH = 3). Soya bean powder (10 g) and culture fluid (80 ml) were added to each 100 g of rice and the mixture was sterilized in steam at 121°C. After cooling below 40°C, the mixture was inoculated with *Monascus pilosus* Sato (AS 3.4444), then cultured at 30-34°C for 3-4 days, then cultured for over 10 days at 100-121°C and then dried.

This Red Rice preparation was further processed into concentrates by using alcohol (75%) extraction. Small amounts of dissolvable starch were added for pill preparation.

(F) Culture fluid was also prepared using 3% potato juice, 5% sugar, 6% thick beef juice and water (pH = 3). 10-20% peanut powder was added to culture fluid (80 ml) for each 100 g of rice, and the mixture was sterilized in steam at 121°C. After cooling below 40°C, the mixture was inoculated with *Monascus ruber* van Tieghem (CGMCC No. 0315) and then cultured at 30-34°C for 3 days. The temperature was lowered to 24°C and the culturing was continued for over 15 days. The mixture was sterilized in steam at 100-121°C and dried.

(G) A medium was also prepared containing 3% corn juice or 3% potato juice, 6% sugar, 1.5% yeast extract powder, 4.5% peptone and water (pH = 3). 5-20% of soya-bean cake powder and 80 ml of culture fluid were added to each 100 g of millet. The mixture was sterilized in steam at 121°C, cooled to a temperature below 40°C, inoculated with *Monascus pilosus* (AS 3.4633), and cultured at 25°C for over 18 days. The mixture was sterilized at 121°C and then dried under a vacuum at a temperature of 60-80°C.

(H) A medium was prepared containing 4% potato juice, 7% sugar, 8% peptone and water (pH = 3). Culture fluid (60 ml) was added to each 100 g of rice, and the mixture was sterilized at 121°C. After cooling to a temperature below 40°C, the mixture was inoculated with *Monascus pubigerus* Sato (AS 3.4445), and then cultured at 30-34°C for 3 days. The temperature was lowered to 25°C and culturing was continued for over 9 days. The mixture was sterilized in steam at 121°C and dried at 80°C.

(I) A medium was prepared containing 5% soya bean milk, 5% glucose, 2%

yeast extract powder, 5% soya-bean peptone and water (pH = 3). Culture fluid (80 ml) was added to each 100 g of rice and the mixture was sterilized in steam at 121°C. After cooling to a temperature below 40°C, the mixture was inoculated with *Monascus pilosus* Sato (AS 3.4646), and cultured at 30-34°C for 3 days. The temperature was lowered to 23-25°C, and cultured for over 9 days. The mixture was sterilized in steam at 121°C and then dried at 80°C.

(J) A medium was prepared containing 4% potato juice, 4% sugar, 3% yeast extract powder and water (pH = 3). Silkworm chrysalis powder (5 g) and culture fluid (60 ml) were added to each 100 g of rice and the mixture was sterilized in steam at 121°C. After cooling to a temperature below 40°C, the mixture was inoculated with *Monascus fuliginosus* Sato (AS 3.569), and then cultured at 30-34°C for 3 days. The temperature was lowered to 23-25°C and culturing was continued for over 9 days. The mixture was sterilized in steam at 121°C and dried under vacuum at 60-80°C.

(K) A medium was prepared containing 3% malt juice, 5% sugar, 6% thick beef juice and water (pH = 3). Culture fluid (80 ml) was added to each 100 g of rice, and the mixture was sterilized in steam at 121°C. After cooling to a temperature below 40°C, the mixture was inoculated with *Monascus fuliginosus* Sato (AS 3.1098), and then cultured at 30-34°C for 3 days. The temperature was lowered to 23-25°C and culturing continued for over 9 days. The mixture was sterilized in steam at 121°C and dried at a temperature of 80°C.

(L) The following procedures were used for large scale fermentation:

(1) Soaking the rice: Rice (500 kg) was placed in several layers of baskets. The chaff was cleaned in water, and the rice soaked in water for 16-24 hours. The rice was dredged from the water and dried (the content of water is approximately 22-24%).

(2) Steaming the rice: Dried rice was poured into a rice steamer and steamed for 50-70 minutes. The steamed rice was spread out on a bamboo mat or in baskets, dispersed, and cooled to a temperature below 40°C. The rice was then inoculated with approximately 20 kg of solid *Monascus* strain and 2.5-3 kg of acetic acid and stirred.

(3) Fermentation: For the first 3 days, the rice was turned over several times

per day. The temperature was controlled between 30°C and 34°C. After 3 days, the temperature was reduced to 23-25°C. The rice was turned over once daily, during which water (pH value adjusted to 3.5 using acetic acid) was added at quantity depending on the humidity of the fermenting mixture. The mixture was fermented for
5 over 15 days.

(4) Preservation: After the fermentation process, the mixture was sterilized, dried and preserved.

The large-scale fermentation methods were used with all media and preparative processes described above by adding in the respective proportions of
10 other ingredients. It should be noted that forced ventilation can be used in the fermentation process but that the return air must be sterile.

Example 2 - Pharmacology and Toxicology

Pharmacological and toxicological studies of the red rice of the present
15 invention were performed in experimental animal models. Red rice was shown to dramatically decrease serum total cholesterol (TC) of endogenous hyperlipidemic rabbits, remarkably decrease TC and total triglyceride (TG) of exogenous hyperlipidemic rabbits, inhibit formation of arteriosclerosis plaque and lipid deposition in liver in hyperlipidemic rabbits, and decrease serum TC and TG of
20 hyperlipidemic quails.

In acute toxicity studies, a LD₅₀ value cannot be determined. The highest tolerance dose of red rice in mice is over 16 g/kg, which is 533 times over the dose used in clinical treatment. Moreover, in other experiments, rats were continuously force-fed red rice for four months; no rats died or showed toxic symptoms due to this
25 drug. Hematological indices, main viscera indices, blood biological indices, routine uroscopy and pathological examination did not show any differences between experimental groups and control groups.

Example 3 - Human Clinical Study I

30 The following two examples contain the methodologies and results of two human clinical trials that were carried out in China. The trials were designed to determine the efficacy of a red rice product in modulating circulating serum lipid and

lipoprotein levels in humans, in resolving symptoms according to traditional Chinese medicine, and in establishing the safety of a red rice product.

In the first randomized human clinical trial, 446 patients with hyperlipidemia, who were also diagnosed as suffering from hypofunction and disorder of the spleen by traditional Chinese medicine, were divided into two treatment groups.

The first group (324 patients) received Xuezhikang capsules, which contained 0.3 g of a red rice product. The second group (122 patients) served as a control; they received Jiaogulan tablets containing a lipid-regulating drug (*Gynostemma pentaphyllum*) that is based on traditional Chinese herbal medicine.

All the patients with primary hyperlipidemia stopped using serum lipid modulators two to four weeks prior to the beginning of the trial and received dietary advice. Serum samples were taken and laboratory tests were conducted to determine eligibility for the study. Only patients who met the following criteria were enrolled in the trial: total serum cholesterol (TC) > 230 mg/dl (5.95 mmol/L) and triglyceride (TG) > 200 mg/dl (> 2.26 mmol/L/L). High density lipoprotein cholesterol (HDL-C) was also considered as a reference; male < 40 mg/dl (1.04 mmol/L), female < 45 mg/dl (1.16 mmol/L). All patients were diagnosed as deficient in the function of the spleen and having excess expectoration by traditional Chinese medicine. The patients also had the following symptoms: limb weakness; asthenic breathing; pain and oppressed feeling in chest; loss of appetite; distention and swelling on gastric region; whitish or purple dots on the tongue; thick-white or thick-slimy fur on the tongue; taut-slippery or hesitant-weak pulse.

Patients who had the following disorder or disease were excluded from the trial: myocardial infarction; cerebrovascular disease; severe wound or major surgery during the past half year; nephritic syndrome; hypothyroidism; acute and/or chronic hepatobiliary disorder; diabetes; gout; general allergic reactions; and psychosis.

The total number of patients enrolled was 446. In the group treated with red rice, there were 188 male and 126 female patients. The ratio of male versus female was 1.38:1 and the average age was 56.0 ± 9 years old. There were 73 male and 45 female patients in the control group. The ratio of male versus female was 1.49:1 and average age was 56.4 ± 9.1 years old. Between the two groups, there was no difference ($P > 0.05$) found in baseline parameters including age, sex and course of disease,

serum lipid and lipoprotein levels.

The group receiving red rice treatment took two Xuezhikang capsules orally, twice a day for 8 weeks. The control group took three Jiaogulan tablets twice a day for 8 weeks. All the patients maintained the same lifestyle and habits as before.

5 The following tests were performed at four and eight weeks: measurements of weight, blood pressure, and cardiac rhythm were performed. In addition, an electrocardiogram and routine physical examination was performed. The following parameters were monitored by laboratory tests: blood urea nitrogen (BLTN); creatinine; serum glutamic pyruvic transaminase (SGPT, ALT); serum glucose; and
10 creatinine kinase (CK).

To determine serum lipid and lipoprotein levels, a fasting (12 hours) venous blood sample was taken from patients who were told not to consume alcoholic beverages or food with a high fat content at the last meal prior to the tests. Serum obtained from the patients was separated immediately, and stored in -20°C for
15 analysis. TC, TG and HDL-C were analyzed, and the LDL-C value was calculated according to the formula: $LDL-C = TC - HDL-C - (TG/2.2)$.

Efficacy of treatment was evaluated according to the criteria set forth in "Clinical trial management: hyperlipidemia treatment using new Chinese materia medica" released by the Ministry of Health of China as follows:

20 1. Cure: All symptoms were eliminated or a reduction of the total symptom score by more than 90%, and a return of all laboratory test parameters to normal.

2. Effective: Symptoms were significantly relieved, i.e., symptom score reduced by 70%-89%. Serum lipid and lipoprotein did not reach normal, but were improved in one of the following respects: 1) reducing TC $\geq 20\%$; 2) reducing TG \geq
25 40%; 3) reducing (TC-HDL-C)/HDL-C $\geq 20\%$; 4) increasing HDL-C >10 mg/dl.

3. Improvement: symptoms were relieved, i.e., symptom score reduced by 30%-69%. Serum lipid and lipoprotein levels were not normal but were improved in one of the following respects: 1) reducing TC at 10%-20%; 2) reducing TG $\geq 20\%$ but $<40\%$; 3) reducing (TC-HDL-C)/HDL-C $\geq 10\%$ but $<20\%$; 4) increasing HDL-C
30 >4 mg/dl (0.14 mmol/L but <10 mg/dl).

4. Inefficacy: Symptom score was reduced by less than 30%, and the laboratory test parameters did not meet the criteria of effectiveness.

All the data are subjected to statistical analyses (the Student's t test, Chi-square test, Ridit assay for data of stratum, and U chart for percentiles analysis were used as appropriate).

Table 1: Efficacy comparison

	Case number	Cure		Effective		Improvement		Inefficacy		Total Effective		Improvement	
		n	%	n	%	n	%	n	%			n	%
Treated Group	324	169	52.2	89	27.5	44	13.5	22	6.8	258	79.7	302	93.2
Control Group	122	13	10.7	25	20.5	24	19.7	60	49.2	38	31.1	62	50.8

Ridit Analysis: $u=10.04$, $p<0.001$

Table 2: Comparison of serum lipid and lipoprotein levels after treatment

Parameter	Group	Case No.	Mean±S Baseline mg/dl	Difference after 4 week difference in mg/dl	% Change	Difference after 8 week difference in mg/dl	% Change
TC	Treated Control	251 94	273.5±31.3 268.2±25.4	-47.4 -13.2	-17.3** -4.9**	-62.8 -18.9	-23** -7**
TG	Treated Control	183 72	296.0±75.5 289±71.7	-66.3 -27.5	-22.4** -9.5*	-108 -42.3	-36.5** -14.6**
HDL-C	Treated Control	121 55	35.9±4.4 35.1±4.0	4.2 1.8	11.8** 5*	7 3	19.6** 8.6**
LDL-C	Treated Control	324 122	162.2±52.4 157.3±49.2	-36.5 -9	-22.5** -5.7**	-46.3 -12.6	-28.5** -8**
TC-HDL-C/ HDL-C	Treated Control	324 122	4.69±1.44 4.79±1.71	1.3 0.39	-22.7** -8.1**	01.6 -0.52	-34.2** -10.9**

Note: (+) indicates increase, (-) indicates decrease

*:p<0.01, **:p<0.001 vs. baseline

+:p<0.05; ++:p<0.01; +++:p<0.001 vs. control

Table 1 shows a comparison of overall efficacy. The score for the group which received red rice (treated group) was much higher than that in the control group ($X^2=9.7$, $P<0.001$).

5 The percentage of patients in the treated group who reported the elimination of symptoms diagnosed by traditional Chinese medicine was much higher than that in the control group ($p<0.05$ -0.001). Those symptoms were: condition of tongue (whitish or purple dots on the tongue; thick-slimy fur); pulse (slippery-taut or hesitant-weak); oppressed feeling in chest; loss of appetite; abdominal distention and swelling.

10 With respect to serum lipid and lipoprotein level, the efficacy scores for curing or reducing total serum cholesterol and total triglyceride level in the treated group were greater than that in the control group. The score for normalizing or increasing HDL-C, level and the score for reducing Atherosclerotic Index in the treated group were also much better than the control ($P<0.001$).

15 Table 2 indicates that both Xuezhikang-treated and control groups showed marked desirable changes in the levels of TC, TG, (TC - HDL-C)/HDL-C, HDL-C serum levels markedly. The effectiveness of Xuezhikang was found to be superior to that of Jiaogulan.

20 It was also observed that the higher the baseline of TC and TG in the serum, the more effective is the reduction of TC and TG after using Xuezhikang. As for HDL-C level, a greater increase was observed after treatment in patients who had a lower starting baseline.

Table 3: Effects of Xuezhikang capsule on patients with different abnormal levels serum lipid and lipoprotein.

Parameter	TC (mg/g)		TG (mg/g)		HDL-C (mg/dl)	
	<230	230-300	>300	<230	230-300	>300
Case No.	73	206	45	141	112	71
Mean baseline (mean)	187.8	261.8	327.1	134.3	247.6	327.3
Difference (4 weeks) % changes	120.5	142.5	169.8	12.7	151.4	189.8
	110.9	116.2	121.3	12	120.8	124.1
Difference (8 weeks) % Changes	130.6	157.9	186.1	115.9	181.4	149.9
	116.3	122.1	126.3	111.8	132.9	140.2
Comparison	**	**	**	**	**	**

(1) indicates the value increase

(1) indicates the value decrease

* P<0.01; ** P<0.001 vs baseline

Table 4: Effect of Xuezhikang capsule on apoA-I and apoB (mean±S)

Group	Case No.	Time Point	apoA-I	apoB	apoA-I/apoB
Treated Group	88	Baseline	1.22±0.19	1.2±0.19	1.05±0.25
		4 Weeks	1.32±0.13(4) 18.2%	1.09±0.21(3) 19.2%	1.25±0.27(5) 119%
		8 Weeks	1.28±0.13 14.9	0.99±0.18(3) 118%	1.33±0.30(3) 126.7%
Comparison Group	30	Baseline	1.19±0.16	1.21±0.15	1.00±0.18
		4 Weeks	1.26±0.11(1) 15.9%	1.15±0.17(1) 15%	1.11±0.14(2) 111.0%
		8 Weeks	1.26±0.09(1) 15.9%	1.03±0.15(3) 114.9%	1.24±0.21(3) 124.0%

(1) P<0.05; (2) P<0.01; (3) P<0.001; vs. baseline
 (4) P<0.05; (5) P<0.05; vs. control

Regarding the effect of Xuezikang on apolipoprotein as a-I (apoA-I) and apolipoprotein B (apoB), the serum levels of apoA-I in both groups were raised after therapy. Statistical results show a significant difference in apoA-I levels after a four week treatment. ApoB levels were reduced somewhat in both groups, however, these reductions are not statistically significant. The treated group showed better improvement of apolipoprotein B and apoA-I/apoB over the control.

With respect to rheology, there were significant changes to in blood sedimentation and K-value in both groups after treatment ($P<0.05-0.01$). However, the treated group showed better results than the control group ($P<0.05-0.01$).

All 446 patients were subjected to the following laboratory tests before and after therapy: blood urea nitrogen (BUN); creatinine; serum glutamic pyruvic transaminase (SGPT, ALT); serum glucose; and creatinine kinase (CK); and routine examination of blood and urine. No clinically meaningful changes were found at the end of the trial.

Several patients developed a burning sensation in the stomach (six patients, 1.8%), experienced fullness in the stomach (three patients, 0.9%), and suffered dizziness (one patient 0.3%). All patients had previously finished the trial, and all the symptoms were spontaneously relieved without treatment. Two patients suffered gastritis after taking Xuezhikang and had to leave the trial. The results suggest that Xuezhikang is a safe and effective drug for lowering serum lipids and triglycerides.

In this trial, a lipid regulating agent known in traditional Chinese medicine was used as a positive control. The efficacy score in the Xuezhikang-treated group was much higher than that in the control group ($P<0.001$). Comparing the baseline, in Xuezhikang-treated group, serum level of high density lipoprotein cholesterol was elevated by 19.6% and total cholesterol, total triglyceride, low density lipoprotein cholesterol and Atherosclerosis Index were reduced by 23%, 36.5%, 28.5% and 34.2%, respectively. It was also observed that the higher the abnormality of the lipid and lipoprotein serum level, the more dramatic the modulation of lipid and lipoprotein levels can be achieved by Xuezhikang therapy. Xuezhikang can also reduce apolipoprotein B level, blood sedimentation and blood sedimentation K-value.

Overall, the results show that red rice was as a safe, effective agent for modulating serum lipid and lipoprotein levels. Red rice can also be used as a

therapeutic agent for coronary artery disease and cerebrovascular disease caused by hyperlipidemia and/or atherosclerosis because red rice not only significantly reduced plasma TC, TG and Atherosclerosis Index, but also markedly raised plasma apolipoprotein in as a-I level.

5

Example 4 - Human Clinical Trial II

In this clinical trial, 84 patients with hyperlipidemia, and 56 patients who were also diagnosed with atherosclerosis were divided into two treatment groups: a group treated with Xuezhikang capsules and a control group treated with Jiaogulan tablets.

10

All patients were diagnosed as hyperlipidemic following the criteria set forth in "Clinical trial management: hyperlipidemia treatment using new Chinese materia medica" released by the Ministry of Health of China. After dietary advice for two to four weeks, blood samples were collected from patients with abnormal lipid and lipoprotein twice, two weeks prior to the trial. Only patients who met the following criteria were enrolled in the trial: total serum cholesterol (TC) > 230 mg/dl (5.95 mmol/L) and triglyceride (TG) > 200 mg/dl (> 2.26 mmol/L). High density lipoprotein cholesterol (HDL-C) was also considered as a reference: male < 40 mg/dl (1.04 mmol/L); female < 45 mg/dl (1.16 mmol/L).

15

The symptoms included: limb tightness; asthenic breathing; pain and oppressed feeling in chest; loss of appetite; distention and swelling of gastric region; whitish or purple dots on tongue; the thick-white or thick-slimy fur on tongue; taut-slippy or hesitant-weak pulse.

20

The severity of the symptoms as recognized by traditional Chinese Medicine were scored as follows:

25

Asthenic breathing

	0	none	(-)	no asthenic breathing
	2	light	(+)	having asthenic breathing with physical activity
30	3	moderate	(++)	having medium asthenic breathing with physical activity
	4	severe (+++)		having asthenic breathing at rest

Limb tightness

	0	none	(-)	no limb tightness
	2	light	(+)	having limb tightness occasionally
	3	moderate	(++)	having medium limb tightness very often
5	4	severe	(+++)	having severe limb tightness

Chest tightness and pain

	0	none	(-)	no chest tightness and pain
	2	light	(+)	having chest tightness and pain occasionally
10	3	moderate	(++)	having medium chest tightness and pain very often
	4	severe	(+++)	having severe chest tightness and pain at rest

Loss of appetite

15	0	none	(-)	having normal appetite
	2	light	(+)	losing appetite by 1/4 - 1/3
	3	moderate	(++)	losing appetite by 1/3 - 1/2
	4	severe	(+++)	losing appetite more than 1/2

20 Abdominal distention and swelling

	0	none	(-)	no this sign
	2	light	(+)	having the sign occasionally
	3	moderate	(++)	having this sign very often
25	4	severe	(+++)	having severe abdominal distention and swelling

Picture of the tongue

	0	normal	(-)
	1	abnormal	(+)

Pulse condition

0	normal	(-)
1	abnormal	(+)

5	Symptom severity:	light:	score \leq 12
		moderate:	score 12-20
		severe:	score $>$ 20

10 Patients diagnosed by traditional Chinese medicine according to the above symptoms, and patients with primary hyperlipidemia were enrolled.

The criteria for exclusion of patients were as follows:

- a. myocardial infarction, cerebrovascular disease, severe wound or major surgery during last half year;
- b. nephritic syndrome, hypothyroidism, acute and/or chronic hepatobiliary
- 15 disorder, diabetes, gout;
- c. familial hypercholesterolemia (monogenic-hypercholesterolemia);
- d. secondary hyperlipidemia caused by other medication, for instance: phenothiazine, beta-adrenergic blocking agents, corticosteroid, oral contraceptive;
- e. patients who used other lipid modulators during the last four weeks and
- 20 patients using heparin or were on thyroidization;
- f. pregnant and breast-feeding women;
- g. patients with disorder of the other organs; and
- h. hylaxis syndrome, and psychosis.

25 The total number of patients enrolled was 116. There were 84 patients in the treated group and 32 patients in the control group. No difference of distribution in age, sex and course of disease were found between the two groups.

A randomized single-blind trial was conducted with two groups. The treated group (84 cases) took two Xuezhikang capsules (i.e., a red rice product of the present invention) twice a day. The control group (32 cases) took three Jiaogulan tablets

30 (ShanXi factory of Chinese materia medica, lot number: 940730) twice a day. The course of treatment was eight weeks.

The measurements of serum lipid and lipoprotein levels and other scoring

were performed prior to the therapy, and at four weeks and at eight weeks after therapy. The safety tests were conducted before and after therapy. A fasting venous blood sample was collected; patients were not allowed to consume alcohol or food with a high fat content in the last meal.

5 The following safety tests were conducted: blood and urea nitrogen (BUN); creatinine; serum glutamic pyruvic transaminase (SGPT, ALT); serum glucose; and creatinine kinase (CK). Total serum cholesterol (TC), total serum triglyceride (TG) and high density lipoprotein cholesterol levels were measured to determine efficacy. Other relevant clinical sign such as weight, high blood pressure, heart beat and
10 rhythm, and hepatospleno-palpation were recorded.

Efficacy was evaluated according to the criteria set forth in "Clinical trial management: hyperlipidemia treatment using new Chinese materia medica" released by the Ministry of Health of China as follows:

- 15 1. Cure: All symptoms are eliminated or the total symptom score reduced by more than 90%; and every laboratory tested parameters reached normal levels.
2. Effective: Symptoms are significantly relieved, i.e., symptom score reduced by 70%-89%. Serum lipid and lipoprotein do not reach normal level but was improved in one of the following respects: 1) reducing TC \geq 20%; 2) reducing TG \geq 40%; 3) reducing (TC- HDL-C)/HDL-C \geq 20%; 4) increasing HDL-C $>$ 10 mg/dl.
- 20 3. Improvement: Symptoms are relieved, i.e., symptom score reduced by 30%-69%. Serum lipid and lipoprotein did not reach normal levels but were improved in one of the following respects: 1) reducing TC at 10%-20%; 2) reducing TG \geq 20% but $<$ 40%; 3) reducing (TC-HDL-C) /HDL-C \geq 10% but $<$ 20%; 4) increasing HDL-C $>$ 4 mg/dl (0.14 mmol/L).
- 25 4. Inefficacy: Symptom score was reduced by less than 30% and laboratory test parameters did not meet the criteria of effectiveness.

All the data were subjected to statistical analysis. The student's t test, Chi-square test for counting data, and Ridit assay were used when appropriate.

Table 5 shows a comparison of the overall efficacy score of the two groups.

Table 5: General Efficacy

Group	Total Case Number	Cure	Effective	Improvement	Inefficacy
Treated	84	39	25	13	7
Control	32	3	6	4	19

Ridit Analysis: $u=5.18$, $P<0.01$

Comparison: $X^2=0.0$ $P>0.05$

The total efficacy score in the treated group was much higher than that of the control group ($X^2=22.95$, $P<0.01$).

Table 6 shows a comparison of efficacies as defined by the standards of traditional Chinese medicine.

Table 6: Comparison of efficacy

Symptoms	Red Rice			Control			Statistics
	Before	After	Vanish%	Before	After	Vanish %	
Asthenic breathing	35	15	57.1	12	6	50	>0.05
Limbs tight	37	16	56.8	13	7	46.2	>0.05
Oppressed feeling in chest	37	16	56.8	9	5	44.4	*
Chest pain	8	1	87.5	2	1	50	*
Loss of appetite	11	4	63.6	3	2	33.3	*
Distension & swelling stomach	31	11	64.5	7	6	14.3	*
Pale tongue	54	34	37	17	12	31.3	>0.05
Purple dot on tongue	9	4	55.6	3	4	0	*
Thick-whitish fur	21	16	23.8	11	6	45.5	>0.05
Thick-slimy fur	11	8	27.3	5	4	0	

Slippery & string-like pulse	28	22	21.4	13	8	33.3	*
Weak-thread pulse	24	16	33.3	8	3	62.6	*
Slippery-fine pulse	28	16	42.9	9	8	11.1	*

*P<0.05 vs control

The percentage of patients who reported elimination of the symptoms as diagnosed by traditional Chinese medicine in the treated group was much higher than that in the control group ($p < 0.05$), especially in the aspect of pain and oppressed feeling in chest, loosing appetite, distention and swelling on gastric region as well as purplish dots on the tongue.

The change in serum total cholesterol level is shown in Table 7.

Table 7: Change in serum total cholesterol level

Group	Abnormal Case No.	Cure	Reduction >20%	Reduction 10-20%	Reduction <10%
Treated	76	53	9	5	9
Control	28	4	0	2	22

Ridit Analysis: $u=5.47$ $P > 0.05$

Efficacy ratio: $X^2 = 39.96$, $P < 0.001$, vs. control

The scores for curing or reducing total serum cholesterol level in the treated group were greater than that in the control group.

The change in serum total triglyceride level is shown in Table 8.

Table 8: Change in serum total triglyceride level

Group	Abnormal Case No.	Cure	Reduction >20%	Reduction 10-20%	Reduction <10%
Treated	35	20	2	5	9
Control	13	6	2	1	4

Ridit Analysis: $u=0.53$ $P > 0.05$

Efficacy ratio: $X^2 = 0.007$, $P < 0.05$, vs. control

No significant difference in the scores for curing or reducing the serum total triglyceride level was observed between the two groups.

The change in high density lipoprotein-cholesterol level is shown in Table 9.

Table 9: Change in HDL-C levels.

Group	Abnormal (>4) Case No.	Cure >4	Reduction >20%	Reduction 10-20%	Reduction <10%
Treated	24	11	1	3	9
Control	10	3	0	1	6

Ridit Analysis: $u=1.03$ $P>0.05$

Efficacy ratio: $X^2 = 1.15$, $P<0.05$, vs. control

A similar efficacy for normalizing or increasing HDL-C level was found in both groups.

Table 10 shows the changes in Atherosclerotic Index which is the ratio of (TC-HDL-C)/HDL-C.

Table 10: Change of (TC-HDL-C) /HDL-C

Group	Abnormal (>4) Case NO.	Cure >4	Reduction >20%	Reduction 10-20%	Reduction <10%
Treated	56	44	6	3	3
Control	14	3	1	2	8

Ridit Analysis: $u=3.84$ $P>0.01$

Efficacy ratio: $X^2 = 23.41$, $P<0.01$, vs. control

The data in Table 10 indicates that the both the Xuezhikang-treated and control groups improved HDL-C serum levels markedly. The effectiveness of Xuezhikang was found to be superior to that of the control.

Table 11 shows the effect of Xuezhikang on regulating serum lipid and lipoprotein levels ($X \pm S$).

Table 11: Regulating Effect of Xuezhikang on serum lipid and lipoprotein (X±S)

Group	Time Point	Case No.	TC (mg/dl)	Case No.	TG (mg/dl)	Case No.	HDL-c (mg/dl)	Case No.	LDL-c (mg/dl)
Treated Group	Baseline	76	273.9±34.1	35	304.1±86.8	24	35.3±4.8	84	174.7±48.1
	4 Weeks difference		253.9±35.9 35*** ↓13.87%		270.3±121.2* 33.8 ↓11.11%		39.5±9** 4.2# ↓11.9%		141.4±477.6*** 33.3### ↓119.1%
	8 Weeks difference		216.7±33.7 57.3*** ↓20.91%		206.5±72*** 97.6 ↓32.09%		42.1±7.6*** 6.8 ↓119.6%		126.8±39.6*** 49.9### ↓127.4%
Control Group	Baseline	28	265.4±25	13	297.1±72.1	10	35.3±3.3	32	164.3±35.6
	4 Weeks difference		272.6±33.3 7.2 ↓12.7		304.8±0.141 7.7 ↓12.6%		35.3±3.7 0.02 ↓10.06%		171.6±42.3 7.3 ↓14.44%
	8 Weeks difference		265±35.8 0.5 ↓10.2%		226.7±88.1 70.3 ↓123.67%		38.3±7.3 2.98 ↓18.43%		168±45.5 4.11 ↓12.5%

↑ Increase *** P<0.001; **P<0.01; *P<0.05 vs baseline

↓ Decrease ### P<0.05) P<0.05 vs. control

Table 11 indicates that Xuezhikang improved TC, TG, (TC - HDL-C)/HDL-C, HDL-C serum levels markedly, but control group only improved TG significantly. Xuezhikang therapy was found to regulate TC, LDL-C more effectively than the control.

- 5 Table 12 shows the efficacy of Xuezhikang therapy on different baseline of serum lipid and lipoprotein.

Table 12: Efficacy comparison of Xuezhikang therapy on different baseline of serum lipid and lipoprotein.

Parameter	TC (mg/g)			TG (mg/g)			HDL-C (mg/dl)		
	<230	230-300	>300	230	230-300	>300	>45	35-45	<35
Case No.	8	60	16	49	20	15	55	17	12
Mean baseline (mean)	192.01	261.8	327.1	134.3	247.6	327.3	56.4	40.1	5.4
Mean (4 weeks)	174.14	226.14	272.56	134.84	202.64	360.59	55.03	43.41	38.82
% Changes	19.31	112.621	117.62	14.05	116.2	16.87	12.68	17.49	124.05
Mean (8 weeks)	156.08	208.21	186.1	119.38	169.51	255.88	57.58	46.89	40.33
% Changes	118.7	119.53	124.93	115.05	129.9	133.91	11.85	116.11	128.89
Comparison	*			**			**		

** P<0.01; * P<0.001 vs. control

The higher baseline of TC and TG in the serum, the more reduction is achieved after using Xuezhikang.

The results indicate that the score of cure, and the score of efficacy were 46.4% (38/84), 29.8% (25/84), respectively, in the Xuezhikang-treated (red rice
5 treated) group and 9.4% (3/32), 18.8% (6/32) in the control group. Total efficacy ratio in the treated group (72%) was much higher than that in the control group (28.2%, $P < 0.001$). There were significant differences between the two groups in terms of improving TC, LDL-C and (TC -HDL-C)/HDL-C.

No significant clinically meaningful change in the following parameters was
10 observed during and after therapy: serum glutamic pyruvic transaminase (SGPT); blood and urea nitrogen (BUN); creatinine; serum glucose; cardioelectrogram; and routine examination of urine and blood. Three cases reported an increase in creatinine kinase (CK) (252, 260, 466 IU/L versus normal standard at 200 IU/L) in the treated group and one (256 IU/L) in the control group. No clinical symptoms
15 were observed in any of these cases. The results show that a red rice product of the present invention is a safe and acceptable lipid-modulating agent.

Other Embodiments

It is to be understood that while the invention has been described in
20 conjunction with the detailed description of thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

WHAT IS CLAIMED:

1. A composition for treating elevated serum cholesterol and/or triglycerides, said composition comprising:
5 a red rice product containing at least about 0.05% lovastatin by weight.
2. The composition of claim 1, wherein said red rice product is the product of a process comprising:
culturing a lovastatin-producing *Monascus* strain in a culture medium
10 comprising rice;
removing said culture medium to provide a solid residue; and
sterilizing said solid residue to provide said red rice product.
3. The composition of claim 2, wherein said *Monascus* strain comprises a
15 strain selected from the group consisting of *Monascus albidus* Sato AS 3.570, AS 3.4440, CGMCC No. 0317; *Monascus pilosus* Sato AS 3.4444, AS 3.4633, AS 3.4646, AS 3.4647; *Monascus pubigerus* Sato AS 3.4445; *Monascus ruber* van Tieghem AS 3.549, CGMCC No. 0315, CGMCC No. 0316; *Monascus paxii* Lingelsheim AS 3.4453; *Monascus fuliginosus* Sato AS 3.569, AS 3.1098, AS
20 3.2091, AS 3.2093, AS 3.2134, IFFI 05035, and *Monascus purpureus* Went CGMCC No. 0272.
4. The composition of claim 2, wherein said process further comprises:
extracting said solid residue with ethanol.
25
5. A method for producing improved red rice, said method comprising:
providing a lovastatin-producing *Monascus* strain;
culturing said *Monascus* strain in a culture medium comprising rice at a
temperature of about 15°C to about 35°C for a period of about 2 to about 20 days to
30 provide crude red yeast rice; and
drying said crude red rice to provide improved red rice.

6. The method of claim 5, wherein said *Monascus* strain comprises a strain selected from the group consisting of *Monascus albidus* Sato AS 3.570, AS 3.4440, CGMCC No. 0317; *Monascus pilosus* Sato AS 3.4444, AS 3.4633, AS 3.4646, AS 3.4647; *Monascus pubigerus* Sato AS 3.4445; *Monascus ruber* van Tieghem AS 3.549, CGMCC No. 0315, CGMCC No. 0316; *Monascus paxii* Lingelsheim AS 3.4453; *Monascus fuliginosus* Sato AS 3.569, AS 3.1098, AS 3.2091, AS 3.2093, AS 3.2134, IFFI 05035, and *Monascus purpureus* Went CGMCC No. 0272.

7. The method of claim 5, wherein said culture medium further comprises:
about 2% to about 6% sugar;
about 2% to about 7% additional carbon source selected from the group consisting of glycerine, malt, potato juice;
about 0% to about 3% peptone;
about 0% to about 3% thick beef juice; and
about 2% to about 4% defoamer.

8. The method of claim 5, wherein said strain is cultured at about 30°C to about 34°C for about 2 to about 4 days, and is then cultured at about 20°C to about 25°C for at least about 4 days.

9. The method of claim 5, which further comprises:
extracting said improved red rice with an ethanol solution to provide an ethanol extract; and
drying said extract.

10. The method of claim 9, wherein said ethanol solution comprises about 75% to about 95% aqueous ethanol.

11. A *Monascus* strain capable of producing about 0.5% lovastatin upon culturing.

12. The *Monascus purpureus* Went strain of claim 11, wherein said strain is selected from the group consisting of *Monascus albidus* Sato AS 3.570, AS 3.4440, CGMCC No. 0317; *Monascus pilosus* Sato AS 3.4444, AS 3.4633, AS 3.4646, AS 3.4647; *Monascus pubigerus* Sato AS 3.4445; *Monascus ruber* van Tieghem AS 3.549, CGMCC No. 0315, CGMCC No. 0316; *Monascus paxii* Lingelsheim AS 3.4453; *Monascus fuliginosus* Sato AS 3.569, AS 3.1098, AS 3.2091, AS 3.2093, AS 3.2134, IFFI 05035, and *Monascus purpureus* Went CGMCC No. 0272.

13. A method of treating or preventing cardiovascular disorders in a mammal which comprises:
administering to a mammal an effective amount of a red rice fermentation product comprising 0.5% lovastatin.

14. The method of claim 13 wherein said red rice fermentation product is produced from the fermentation of at least one lovastatin-producing *Monascus* strain.

15. The method of claim 13 wherein said cardiovascular disorder is selected from the group consisting of myocardial infarction, coronary heart disease, hypertension, hypotension, atherosclerosis and arteriosclerosis.

16. A method of treating or preventing stroke, cerebral thrombosis which comprises administering an effective amount of a red rice fermentation product.

17. A method of treating or preventing fatty liver conditions in a human which comprises administering to a human an effective amount of a red rice fermentation product.

18. A method of reducing serum cholesterol and triglyceride levels to normal levels in a human in need of such therapy which comprises administering an effective amount of a red rice fermentation product.

19. A pharmaceutical or nutritional formulation for treating elevated

serum cholesterol and/or triglyceride levels, said formulation comprising:
an effective amount of a red rice product; and
a pharmaceutically acceptable excipient.

5

20. The formulation of claim 19, wherein said formulation comprises
about 10 mg lovastatin.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 35/70, C12P 1/02, C12N 1/14, A23L 1/28	A3	(11) International Publication Number: WO 99/23996 (43) International Publication Date: 20 May 1999 (20.05.99)
(21) International Application Number: PCT/IB98/01918 (22) International Filing Date: 6 November 1998 (06.11.98) (30) Priority Data: 08/965,202 6 November 1997 (06.11.97) US (71) Applicant (for all designated States except US): PEKING UNIVERSITY [CN/CN]; 5 Yiheyuan Road, Haidian District, Beijing 100871 (CN). (72) Inventors; and (75) Inventors/Applicants (for US only): ZHANG, Mao, Liang [CN/CN]; Room 619-623, Beijing Aero Space Great Wall Building, 30 Haidian Nan LU, Beijing 100080 (CN). PENG, Chi-Xiu [CN/CN]; Room 619-623, Beijing Aero Space Great Wall Building, 30 Haidian Nan LU, Beijing 100080 (CN). ZHOU, Yu-Fang [CN/CN]; Room 619-623, Beijing Aero Space Great Wall Building, 30 Haidian Nan LU, Beijing 100080 (CN). (74) Agents: XIAO, Jin et al.; CCPIT Patent and Trademark Law Office, 8th floor, 2 Fuchengmenwai Street, Beijing 100037 (CN).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 19 August 1999 (19.08.99)
(54) Title: COMPOSITIONS CONTAINING RED RICE FERMENTATION PRODUCTS, FREMENTATION PROCESSES AND MONASCUS STRAINS THEREFOR (57) Abstract <p>Methods and compositions are disclosed which comprise red rice fermentation products, that can be used as natural dietary supplements and/or medicaments for the treatment or prevention of hyperlipidermia and associated disorders and symptoms, such as cardiovascular diseases, cerebrovascular diseases, diabetes, hypertension, obesity, asthenic breathing, chronic headache, chest pain and tightness, limb swelling and distention, loss of appetite and excess expectoration. The methods and compositions are effective in lowering both the serum cholesterol and serum triglyceride levels in human, and can be used for maintaining cardiovascular health. The invention also encompasses particular <i>Monascus</i> strains that yield fermentation products with the desired biological activities.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB98/01918

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁶ A61K35/70, C12P1/02, C12N1/14, A23L1/28

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched(classification system followed by classification symbols)

IPC⁶ A61K35/66-35/74, C12P1/02, C12P17/, C12P7/, C12N1/14, A23L1/28

Documentation searched other than minimum documentation to the extent that such documents are included in the field searched

Chinese Patent Documentation

Electronic data base consulted during the international search(name of data base and, where practicable, search terms used)

WPI(Derwent), CNPAT(CN), PAJ(JP), EPODOC(EP)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant claim No.
X	CN,A,1155421 (ZHANG MAOLIANG) 30.Jul.1997(30.07.97), see the whole document	1-12,19-20
A	CN,A,1075875 (PEKING UNIVERSITY) 08.Sep.1993(08.09.93), see the whole document	1-10,19-20
A	CN,A,1110560 (SHIXIN MEDICINE TECHNOLOGY DEV CENT CHEN) 25.Oct.1995(25.10.95), see the whole document	1-4,19-20
A	CN,A,1106230 (YUAN BAOSHAN) 09.Aug.1995(09.08.95), see the whole document	19-20

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason(as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20.Apr.1999(20.04.99)

Date of mailing of the international search report

10 JUN 1999 (10.06.99)

Name and mailing address of the ISA/

The Chinese Patent Office
6, Xitucheng Road, Haidian District,
Beijing, 100088, China

Facsimile No. 86-010-62019451

Authorized officer

DONG, Fang

Telephone No. 86-010-62093031



INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB98/01918

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P	CN,A,1173361 (ZHU JIANZHONG) 18.Feb.1998(18.02.98), see the whole document	1-10,19-20
A	JP,A,58-43783 (AKIRA ENDOU) 14.Mar.1983(14.03.83), see the whole document	1-3,5-8, 11-12,19-20
A	JP,A,63-198973 (GUNZE LTD) 17.Aug.1988(17.08.88), see the whole document	1-3,5-8, 11-12,19-20
A	JP,A,62-132878 (NIPPON KAYAKU CO LTD) 16.Jun.1987(16.06.87), see the whole document	1-12,19-20
A	JP,A,55-150898 (SANKYO CO LTD) 25.Nov.1980(25.11.80), see the whole document	1-12,19-20
A	CHINESE PHARMACEUTICAL JOURNAL, vol.30, no.11, Nov.1995 (42 Dongsì Xidajie, Beijing, China), ZHU, Yan et al., "Effects of Xuezhikang on blood lipids and lipoprotein concentrations of rabbits and quails with hyperlipidaemia", pages 656-660, see the whole document	1-4,19-20
A	MICROBIOLOGY, vol.21, no.5, Oct.1994 (16 Dong-huang-cheng-gen-bei Street, Beijing, China), HAN, Mei et al., "Experimental Study on the Decholesterolization of Metabolites from <i>Monascus ruber</i> ", pages 279-280, see the whole document	1-4,19-20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB98/01918**Box I. Observations where certain claims were found unsearchable(Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13-18
because they relate to subject matter not required to be searched by Authority, namely:
These claims relate to methods for the treatment of diseases(see PCT rule 39.1(iv)).
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II. Observations where unity of invention is lacking(Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/IB98/01918

Patent document cited in search report	Publication date	Patent family members	Publication date
CN 1155421A	30.07.97	CN 1174037A	25.02.98
CN 1075875A	08.09.93	None	
CN 1110560A	25.10.95	None	
CN 1106230A	09.08.95	None	
CN 1173361A	18.02.98	None	
JP 58-43783A	14.03.83	None	
JP 63-198973A	17.08.88	None	
JP 62-132878A	16.06.87	None	
JP 55-150898A	25.11.80	BE 882325A	19.09.80
		SE 8001338A	12.11.80
		DK 73180A	12.11.80
		AU 5667880A	13.11.80
		NL 8001697A	13.11.80
		DE 3006215A	27.11.80
		FR 2456141A	05.12.80
		GB 2049664A	31.12.80
		US 4323648	06.04.82
		CA 1129795A	17.08.82
		AT 372975B	12.12.83
		AU 534647B	09.02.84
		CH 645891A	31.10.84
		SE 8701483A	09.04.87